The values of applying classification and counts of white blood cells to the prognostic evaluation of resectable gastric cancers

Wang, Yin-Ling; Ge, Xin-Xin; Wang, Yi; Xu, Mengdan; Gong, Fei‐Ran; Tao, Min; Wang, Wenjie; Shou, Liu‐Mei; Chen, Kai; Wu, Mengyao; Li, Wei

doi:10.1186/s12876-018-0812-0

Cited by 17 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 In gastric cancer, treatment modality has an impact on total white blood cells count, and neutrophil, lymphocyte, monocyte, eosinophil and basophil counts. 8 NLR was found to be significantly associated with tumor grade and progression, but its mean values in different groups proved to be significant with tumor grade, tumor stage, and progression. A random model (I 2 = 57.8%) showed that pretreatment high NLR has poor RFS (pooled HR = 2.31; 95% CI = 1.27-2.22; p = 0.006) and poor PFS (pooled HR = 2.14, 95% CI = 1.59-2.87; p = 0.001).…”

Section: Discussionmentioning

confidence: 81%

“…Chronic/systemic inflammation in cancer can be assessed by evaluation of neutrophil to lymphocyte ratio (NLR), absolute basophil count, absolute monocyte count, and absolute eosinophil count. 7,8 High NLR is a predictor of recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) in various malignancies, including urinary bladder cancer (UBC), colorectal cancer, and prostate cancer. [9][10][11] Body mass index (BMI) is the calculative marker for obesity and its relation to UBC prognosis has been recently studied by Ferro and colleagues.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oct-4: a prognostic biomarker of urinary bladder cancer in North India

Siddiqui

Srivastava

Sankhwar

et al. 2019

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: The objective of this study was to evaluate Octamer-binding transcription factor 4 (Oct-4), neutrophil to lymphocyte ratio (NLR) and body mass index (BMI) as independent prognostic biomarkers for prediction of urinary bladder cancer (UBC) outcomes. With the advancement in prognostic biomarker discovery, tumor recurrence is difficult to accurately predict in UBC. UBC is costly to treat due to the requirement of frequent invasive follow-up sessions. Therefore, it is of utmost importance to evaluate good prognostic biomarkers for UBC surveillance. Methods: We studied 39 UBC tissue samples. Oct-4 protein expression was evaluated semiquantitatively by immunohistochemistry (IHC). Complete blood count data and body weight as well as the height of the patients were retrieved and recorded before the date of the first transurethral resection of bladder tumor (TURBT). The follow-up period was 48 months for recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). Results: Oct-4 expression profile was found to be significantly associated with gender ( p = 0.028), tumor grade ( p = 0.038), tumor stage ( p = 0.003), lymph node status ( p = 0.029), recurrence ( p = 0.004), progression ( p = 0.011), and treatment modality ( p = 0.016). Tumor grade and progression were found significant with NLR values (tumor grade, p = 0.006; progression, p = 0.038) and BMI (tumor grade, p = 0.036; progression, p = 0.014). Moreover, BMI was also significantly associated with UBC recurrence ( p = 0.014). Kaplan–Meier survival analysis showed poor prognosis with both high Oct-4 expression (RFS, p = 0.001; PFS, p = 0.004; OS, p = 0.014) and high NLR values (RFS, p = 0.049; PFS, p = 0.004; OS, p = 0.005). Patients with high BMI too had poor RFS ( p = 0.025) and poor PFS ( p = 0.032). Furthermore, multivariate Cox regression analysis, indicated Oct-4 as an independent prognostic biomarker for RFS (HR = 0.240, 95% CI, 0.072–0.804, p = 0.021). Conclusions: We conclude that the expression profile of Oct-4 will be beneficial in prediction of UBC recurrence, and could have profound implications on the development of new therapeutic targets for UBC treatment.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Oct-4: a prognostic biomarker of urinary bladder cancer in North India

Siddiqui

Srivastava

Sankhwar

et al. 2019

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…The ability of WBC count and dNLR to predict prognosis for patients with solid tumors has been reported previously. [28][29][30][31] In the present study, our nomogram included both WBC count Open access and dNLR for predicting the probability of mortality in patients with COVID-19 with solid tumors. We found that the mortality risk increased for patients with high WBC counts and dNLR.…”

Section: Discussionmentioning

confidence: 99%

A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study

Liu

Song

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundIndividualized prediction of mortality risk can inform the treatment strategy for patients with COVID-19 and solid tumors and potentially improve patient outcomes. We aimed to develop a nomogram for predicting in-hospital mortality of patients with COVID-19 with solid tumors.MethodsWe enrolled patients with COVID-19 with solid tumors admitted to 32 hospitals in China between December 17, 2020, and March 18, 2020. A multivariate logistic regression model was constructed via stepwise regression analysis, and a nomogram was subsequently developed based on the fitted multivariate logistic regression model. Discrimination and calibration of the nomogram were evaluated by estimating the area under the receiver operator characteristic curve (AUC) for the model and by bootstrap resampling, a Hosmer-Lemeshow test, and visual inspection of the calibration curve.ResultsThere were 216 patients with COVID-19 with solid tumors included in the present study, of whom 37 (17%) died and the other 179 all recovered from COVID-19 and were discharged. The median age of the enrolled patients was 63.0 years and 113 (52.3%) were men. Multivariate logistic regression revealed that increasing age (OR=1.08, 95% CI 1.00 to 1.16), receipt of antitumor treatment within 3 months before COVID-19 (OR=28.65, 95% CI 3.54 to 231.97), peripheral white blood cell (WBC) count ≥6.93 ×109/L (OR=14.52, 95% CI 2.45 to 86.14), derived neutrophil-to-lymphocyte ratio (dNLR; neutrophil count/(WBC count minus neutrophil count)) ≥4.19 (OR=18.99, 95% CI 3.58 to 100.65), and dyspnea on admission (OR=20.38, 95% CI 3.55 to 117.02) were associated with elevated mortality risk. The performance of the established nomogram was satisfactory, with an AUC of 0.953 (95% CI 0.908 to 0.997) for the model, non-significant findings on the Hosmer-Lemeshow test, and rough agreement between predicted and observed probabilities as suggested in calibration curves. The sensitivity and specificity of the model were 86.4% and 92.5%.ConclusionIncreasing age, receipt of antitumor treatment within 3 months before COVID-19 diagnosis, elevated WBC count and dNLR, and having dyspnea on admission were independent risk factors for mortality among patients with COVID-19 and solid tumors. The nomogram based on these factors accurately predicted mortality risk for individual patients.

show abstract

“…Pre-treatment circulating basophil counts were associated with recurrence in patients who received bacillus Calmette-Guerin after transurethral resection of the bladder tumor (38). Pre-treatment basophil counts did not correlate with survival in gastric cancer (39), whereas a higher basophil count was associated with improved outcome in patients with colorectal cancer (40) and in patients with melanoma who received checkpoint inhibitor therapy (41). With a clear distinction between basophils and e-MDSCs, the field will be better equipped to evaluate the roles of these cell populations in the context of newly diagnosed cancer and in response to therapy.…”

Section: Discussionmentioning

confidence: 95%

Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils

Khan

Emmons

Wong

et al. 2020

Cancer Immunology Research

View full text Add to dashboard Cite

Supplementary data -Supplementary Table S1 and Supplementary Fig. S1 Author contributions ANHK and BHS developed the study and wrote the manuscript. ANHK, TRE, EA, BS, and BHS designed and performed experiments and analyzed data. JTW performed morphological analysis and JM performed clinical data analysis. KHE oversaw the statistical analysis. KLS, TRE, JM, and JTW contributed to the manuscript preparation. JDT, KBM, KO, SIA, and BHS provided technical support and conceptual advice. All authors discussed the results and implications and commented on the manuscript at all stages.

show abstract

The values of applying classification and counts of white blood cells to the prognostic evaluation of resectable gastric cancers

Cited by 17 publications

References 49 publications

Oct-4: a prognostic biomarker of urinary bladder cancer in North India

Oct-4: a prognostic biomarker of urinary bladder cancer in North India

A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study

Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils

Contact Info

Product

Resources

About